SynthesisPloS one2020
Treatment effect of posterior scleral reinforcement on controlling myopia progression: A systematic review and meta-analysis.
Synthesis in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- [Research progress and applications of biologically derived materials in scleral reconstruction].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
- Comparison of posterior scleral reinforcement surgery and repeated low-level red-light therapy in controlling high and super high myopia in Chinese children.International journal of ophthalmology · 2026Article
- Pathologic myopia as a concurrent condition in Pierre Robin sequence: a case report and literature review.Frontiers in medicine · 2026Article
- IMI-Interventions for Controlling Myopia Onset and Progression 2025.Investigative ophthalmology & visual science · 2025Review
- A Self-Generated Electricity-Driven Sclera reinforcement bionic piezoelectric patch for Management of High Myopia.Journal of nanobiotechnology · 2025Article
- The Role of Scleral Changes in the Progression of Myopia: A Review and Future Directions.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
- Collagen is crucial target protein for scleral remodeling and biomechanical change in myopia progression and control.Heliyon · 2024Review
- Clinical outcomes of posterior scleral reinforcement in Chinese high myopia children.Scientific reports · 2024Article
- Long-term outcomes of anti-vascular endothelial growth factor therapy with and without posterior scleral reinforcement on myopic maculopathy in myopic choroidal neovascularization eyes.BMC ophthalmology · 2024Article
- Internal limiting membrane peeling combined with silicone oil or air tamponade for highly myopic foveoschisis.International journal of ophthalmology · 2024Article
- Multimodal Analysis on Clinical Characteristics of the Advanced Stage in Myopic Traction Maculopathy.Ophthalmology and therapy · 2023Article
- Posterior scleral birefringence measured by triple-input polarization-sensitive imaging as a biomarker of myopia progression.Nature biomedical engineering · 2023Article
- Clinical Feasibility and Safety of Scleral Collagen Cross-Linking by Riboflavin and Ultraviolet A in Pathological Myopia Blindness: A Pilot Study.Ophthalmology and therapy · 2023Article
- Clinical effect of rigid gas permeable (RGP) contact lens in improving vision and controlling myopia progression of unilateral high myopic children.International ophthalmology · 2022Article
- Biomechanical Considerations of Patching Material for Posterior Scleral Reinforcement Surgery.Frontiers in medicine · 2022Article
- Long-term outcome of pathologic myopic foveoschisis treated with posterior scleral reinforcement followed by vitrectomy.International journal of ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh myopia is a sight-threatening disease that causes axial length elongation and severe complications. Data on the benefits of posterior scleral reinforcement surgery in myopia control have been conflicting. The purpose of this study was to explore the treatment effect and complications of posterior scleral reinforcement in the treatment of myopia.
methodsArticles were retrieved for relevant studies from inception to July 24, 2019, by PubMed, EMBASE, and Ovid. Analyses were conducted to compare the treatment effects of controlling spherical equivalent refraction and axial length elongation. The weighted mean difference and Hedges' adjusted g were used to evaluate the treatment effects, with a random-effects model. Heterogeneity was quantified using I2 statistic and explored by subgroup analysis. Publication bias was addressed by funnel plots and Egger's test.
resultsA total of 11 articles were included in this meta-analysis. On estimating the treatment effect, the mean differences of myopia progression and axial length changes between surgery and control groups were 0.41 diopters per year (95% CI 0.21 to 0.61; P < .001) and -0.17 mm per year (95% CI -0.22 to -0.11; P < .001). Subgroup analysis showed significant treatment effects of the single wide strip operation. Single-arm meta-analysis showed less annual axial elongation in children subgroup. These results were robust by sensitivity analysis. The incidence of some major complications in the operation group were significantly greater (5.8% vs 2.7% for myopic degeneration; 2.3% vs 1.6% for macular hemorrhage; 0.8% vs 0 for retinal detachment).
conclusionPosterior scleral reinforcement may be an effective surgery on controlling myopia progression by slowing both refraction and axial length change. However, frequent surgical complications should be considered. Further well-designed studies are needed to determine the long-term safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.